On May 1, 2026, the FDA published a notice (Docket FDA-2018-N-3240) proposing to exclude the three main GLP-1 substances, semaglutide, tirzepatide, and liraglutide, from the "503B bulks list." It sounds technical, but it decides how compounded GLP-1s can be made. The public comment period closed on July 30, 2026. As of late September 2026 the FDA has not published its final decision, so if access matters to you, keep an eye on this docket.
What the 503B bulks list is
"503B outsourcing facilities" are compounders that make medications in larger volumes under stricter federal oversight than a typical pharmacy. A 503B facility generally cannot compound a drug from a bulk substance unless that substance is on the FDA's "503B bulks list", which lists substances for which the FDA has found a clinical need. A separate pathway was open while the brand-name drugs were in official shortage, but the FDA declared those shortages resolved on December 19, 2024 (tirzepatide) and February 21, 2025 (semaglutide).
So whether semaglutide, tirzepatide, and liraglutide are on this list decides whether 503B facilities can keep compounding them from bulk.
What the FDA is proposing, and why
After reviewing the nominations it received, the FDA says it did not find sufficient evidence of a clinical need for outsourcing facilities to compound these three drugs from bulk substances, and it proposes to leave them off the list. In the notice, the FDA explains how it judges clinical need: it first asks whether some attribute of the FDA-approved product makes it medically unsuitable for certain patients, and whether the compounded version is meant to address that. It says it does not count supply problems such as backorders, convenience, or the lower cost of a compounded product as clinical need.
The notice also shows what each side argued. The nominators pointed to shortages, growing demand, and access to these drugs, which the FDA said fall outside the clinical-need standard. Commenters raised safety and quality concerns about compounded versions, and the FDA said it didn't need to reach those arguments because the drugs failed the first step. We aren't taking a side here. The decision is still open, and there are ways to follow it.
Why it matters for access
If finalized as proposed, this would further narrow the legal routes for 503B-compounded GLP-1s. For patients, the practical questions are cost and whether alternatives are available, and those are the access issues where public comment and patient experience carry weight.
The comment period (closed July 30, 2026) and what happens next
Public comments are part of how the FDA reaches a final decision, and anyone could submit one, including patients, caregivers, and clinicians. The FDA first set a June 30, 2026 deadline, then extended it to July 30, 2026. That window has closed, but the process isn't over.
- The notice and all public comments are posted on regulations.gov as Docket FDA-2018-N-3240 (external link). Reading what patients, clinicians, and organizations submitted is a good way to understand each side's arguments.
- While the period was open, anyone could file through the "Comment" button on the docket page, and personal, specific accounts were often the most useful. If the FDA reopens or extends the period, the same button applies; check the docket page for current status.
- The FDA will publish its final determination as a new Federal Register notice filed to the same docket. Until then, the proposal is not final.
Comments on the docket are public record, so anyone can see what's filed there.
Want to go deeper?
Patient-advocacy organizations like the Obesity Action Coalition track decisions like this and sometimes offer ways to add your voice, which is useful if you want context or a coordinated channel. For the broader access-versus-safety argument behind this docket, see our guide on the compounding pharmacy debate.
This is general information about a public regulatory process, not legal or medical advice. It summarizes an FDA proposal that may change; rely on the official docket for the authoritative text and current status.